Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 105824792 | 10582479 | 2 | F | 20140807 | 20160714 | 20141113 | 20160719 | EXP | US-TAKEDA-2014MPI002975 | TAKEDA | 55.00 | YR | F | Y | 79.37000 | KG | 20160719 | OT | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 105824792 | 10582479 | 1 | PS | VELCADE | BORTEZOMIB | 1 | Subcutaneous | 1.5 MG/M2 | 21602 | 1.5 | MG/M**2 | INJECTION | /wk | ||||||
| 105824792 | 10582479 | 2 | SS | VELCADE | BORTEZOMIB | 1 | Intravenous (not otherwise specified) | 1 MG/M2 | 21602 | 1 | MG/M**2 | INJECTION | |||||||
| 105824792 | 10582479 | 3 | SS | DEXAMETHASONE. | DEXAMETHASONE | 1 | Oral | 40 MG | 0 | 40 | MG | /wk | |||||||
| 105824792 | 10582479 | 4 | SS | DEXAMETHASONE. | DEXAMETHASONE | 1 | Oral | 40 MG | 0 | 40 | MG | ||||||||
| 105824792 | 10582479 | 5 | SS | THALIDOMIDE | THALIDOMIDE | 1 | Oral | 50 MG, QD | 4950 | MG | 0 | 50 | MG | QD | |||||
| 105824792 | 10582479 | 6 | SS | THALIDOMIDE | THALIDOMIDE | 1 | Oral | 200 MG | 4950 | MG | 0 | 200 | MG | ||||||
| 105824792 | 10582479 | 7 | SS | CYTOXAN | CYCLOPHOSPHAMIDE | 1 | Oral | 300 MG/M2 | 0 | 300 | MG/M**2 | /wk | |||||||
| 105824792 | 10582479 | 8 | SS | CYTOXAN | CYCLOPHOSPHAMIDE | 1 | Intravenous (not otherwise specified) | 400 MG/M2 | 0 | 400 | MG/M**2 | ||||||||
| 105824792 | 10582479 | 9 | SS | DOXORUBICIN HYDROCHLORIDE. | DOXORUBICIN HYDROCHLORIDE | 1 | Intravenous (not otherwise specified) | 10 MG/M2 | 0 | 10 | MG/M**2 | ||||||||
| 105824792 | 10582479 | 10 | SS | CISPLATIN. | CISPLATIN | 1 | Intravenous (not otherwise specified) | 10 MG/M2 | 0 | 10 | MG/M**2 | ||||||||
| 105824792 | 10582479 | 11 | SS | ETOPOSIDE. | ETOPOSIDE | 1 | Intravenous (not otherwise specified) | 10 MG/M2 | 0 | 10 | MG/M**2 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 105824792 | 10582479 | 1 | Plasma cell myeloma |
| 105824792 | 10582479 | 3 | Plasma cell myeloma |
| 105824792 | 10582479 | 5 | Plasma cell myeloma |
| 105824792 | 10582479 | 7 | Plasma cell myeloma |
| 105824792 | 10582479 | 9 | Plasma cell myeloma |
| 105824792 | 10582479 | 10 | Plasma cell myeloma |
| 105824792 | 10582479 | 11 | Plasma cell myeloma |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 105824792 | 10582479 | DE |
| 105824792 | 10582479 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 105824792 | 10582479 | Back pain | |
| 105824792 | 10582479 | Death | |
| 105824792 | 10582479 | Mucosal inflammation |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 105824792 | 10582479 | 1 | 20140430 | 20140806 | 0 | |
| 105824792 | 10582479 | 2 | 20140812 | 20140823 | 0 | |
| 105824792 | 10582479 | 3 | 20140630 | 20140806 | 0 | |
| 105824792 | 10582479 | 4 | 20140812 | 20140823 | 0 | |
| 105824792 | 10582479 | 5 | 20140430 | 20140806 | 0 | |
| 105824792 | 10582479 | 6 | 20140812 | 20140823 | 0 | |
| 105824792 | 10582479 | 7 | 20140430 | 20140806 | 0 | |
| 105824792 | 10582479 | 8 | 20140812 | 20140823 | 0 | |
| 105824792 | 10582479 | 9 | 20140812 | 20140823 | 0 | |
| 105824792 | 10582479 | 10 | 20140812 | 20140823 | 0 | |
| 105824792 | 10582479 | 11 | 20140812 | 20140823 | 0 |